Action should be taken against pharmaceutical companies who hike prices of off-patent medicines

The views expressed in this letter are those of the author’s. If you would like to submit a letter to The Pharmaceutical Journal, please click here.

We live in a time where a majority of us, in the UK, take a special pride in our NHS. We are told it’s the envy of much of the world. We know it’s been under tremendous resource strain for many years and generally support year-on-year super-inflationary rises in its funding.

When it comes to theft (and fraud) from the service, we rightly take the moral high ground. Often it is an employee or group of employees simply stealing something and we delight in seeing them publicly shamed and successfully prosecuted. What is sad, though, is a similar shaming doesn’t get meted on the senior executives of pharmaceutical companies who have been caught by a regulator cynically hiking prices of off-patent medicines supplied to the NHS. Will we see them in turn (individually) prosecuted? Will they be named and shamed? What do you think?

Mike Price, retired pharmacist

Last updated
The Pharmaceutical Journal, PJ, August 2021, Vol 307, No 7952;307(7952)::DOI:10.1211/PJ.2021.1.100098

    Please leave a comment 

    You may also be interested in